RS64833B1 - Helatni fosforotioatni polimeri nukleinske kiseline za upotrebu u kombinaciji sa inhibitorom hbv polimeraze za lečenje virusnih infekcija hepatitisa b i hepatitisa d - Google Patents

Helatni fosforotioatni polimeri nukleinske kiseline za upotrebu u kombinaciji sa inhibitorom hbv polimeraze za lečenje virusnih infekcija hepatitisa b i hepatitisa d

Info

Publication number
RS64833B1
RS64833B1 RS20231031A RSP20231031A RS64833B1 RS 64833 B1 RS64833 B1 RS 64833B1 RS 20231031 A RS20231031 A RS 20231031A RS P20231031 A RSP20231031 A RS P20231031A RS 64833 B1 RS64833 B1 RS 64833B1
Authority
RS
Serbia
Prior art keywords
hbv
pharmaceutically acceptable
composition
nucleic acid
treatment
Prior art date
Application number
RS20231031A
Other languages
English (en)
Serbian (sr)
Inventor
Andrew Vaillant
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS64833(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of RS64833B1 publication Critical patent/RS64833B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
RS20231031A 2014-07-10 2015-07-07 Helatni fosforotioatni polimeri nukleinske kiseline za upotrebu u kombinaciji sa inhibitorom hbv polimeraze za lečenje virusnih infekcija hepatitisa b i hepatitisa d RS64833B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462022846P 2014-07-10 2014-07-10
US201462091943P 2014-12-15 2014-12-15
PCT/CA2015/050626 WO2016004525A1 (en) 2014-07-10 2015-07-07 Methods for the treatment of hepatitis b and hepatitis d virus infections
EP15818148.7A EP3166615B1 (en) 2014-07-10 2015-07-07 Chelated phosphorotiotated nucleic acid polymers for use in combination with a hbv polymerase inhibitor for the treatment of hepatitis b and hepatitis d virus infections

Publications (1)

Publication Number Publication Date
RS64833B1 true RS64833B1 (sr) 2023-12-29

Family

ID=55063440

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20231031A RS64833B1 (sr) 2014-07-10 2015-07-07 Helatni fosforotioatni polimeri nukleinske kiseline za upotrebu u kombinaciji sa inhibitorom hbv polimeraze za lečenje virusnih infekcija hepatitisa b i hepatitisa d

Country Status (33)

Country Link
US (1) US9603865B2 (OSRAM)
EP (1) EP3166615B1 (OSRAM)
JP (2) JP2017521433A (OSRAM)
KR (2) KR102734495B1 (OSRAM)
CN (2) CN113750112A (OSRAM)
AU (1) AU2015286199B2 (OSRAM)
BR (1) BR112017000320B1 (OSRAM)
CA (1) CA2954182C (OSRAM)
CL (1) CL2017000008A1 (OSRAM)
CU (1) CU20170001A7 (OSRAM)
DK (1) DK3166615T3 (OSRAM)
DO (1) DOP2017000002A (OSRAM)
EA (1) EA036745B1 (OSRAM)
EC (1) ECSP16097355A (OSRAM)
ES (1) ES2963814T3 (OSRAM)
FI (1) FI3166615T3 (OSRAM)
HK (1) HK1231402A1 (OSRAM)
HR (1) HRP20231400T1 (OSRAM)
HU (1) HUE064449T2 (OSRAM)
IL (1) IL249660B (OSRAM)
LT (1) LT3166615T (OSRAM)
MD (1) MD4760C8 (OSRAM)
MX (1) MX381042B (OSRAM)
MY (1) MY178087A (OSRAM)
PH (1) PH12017500010B1 (OSRAM)
PL (1) PL3166615T3 (OSRAM)
PT (1) PT3166615T (OSRAM)
RS (1) RS64833B1 (OSRAM)
SG (1) SG11201700073PA (OSRAM)
SI (1) SI3166615T1 (OSRAM)
SM (1) SMT202300380T1 (OSRAM)
TW (1) TWI766831B (OSRAM)
WO (1) WO2016004525A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53674A (fr) * 2018-11-08 2021-07-28 Aligos Therapeutics Inc Polymères oligonucléotidiques inhibant le transport de l'antigène s et procédés
US11166976B2 (en) * 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2021119325A1 (en) * 2019-12-12 2021-06-17 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
CN112010905B (zh) * 2020-05-07 2021-09-03 西安新通药物研究股份有限公司 甲磺酸帕拉德福韦晶型及其应用
WO2021223398A1 (zh) * 2020-05-07 2021-11-11 西安新通药物研究股份有限公司 治疗肝病的晶型及其应用
CN114057816B (zh) * 2020-07-30 2025-02-11 浙江柏拉阿图医药科技有限公司 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
US20220160748A1 (en) * 2020-11-20 2022-05-26 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
WO2022261046A1 (en) * 2021-06-07 2022-12-15 Antios Therapeutics, Inc. Compositions and methods of treating hepatitis d and hepatitis b/hepatitis d co-infections with phosphoramidate clevudine prodrugs
WO2023281434A1 (en) 2021-07-09 2023-01-12 Janssen Pharmaceuticals, Inc. Use of oligonucleotides for individuals with renal impairment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482836A (en) * 1993-01-14 1996-01-09 The Regents Of The University Of California DNA purification by triplex-affinity capture and affinity capture electrophoresis
WO2004024919A1 (en) 2002-09-13 2004-03-25 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
WO2006091798A2 (en) * 2005-02-22 2006-08-31 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vaccines and methods for prevention and treatment of drug-resistant hiv-1 and hepatitis b virus
SI2605794T1 (sl) 2010-08-20 2017-01-31 Replicor Inc. Oligonukleotidni kelatni kompleksi
EP3327125B1 (en) * 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
WO2012075114A2 (en) * 2010-12-01 2012-06-07 Ablitech, Inc. Nucleic acid-polymer conjugates and uses thereof
DK2849798T3 (da) * 2012-05-18 2021-05-31 Replicor Inc Oligonukleotid-chelatkompleks-polypeptidsammensætninger og fremgangsmåder
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
WO2014032176A1 (en) 2012-08-30 2014-03-06 Replicor Inc. Methods for the treatment of hepatitis b and hepatitis d infections

Also Published As

Publication number Publication date
HUE064449T2 (hu) 2024-03-28
MD4760C8 (ro) 2022-02-28
AU2015286199A1 (en) 2017-02-23
CN106659730A (zh) 2017-05-10
CA2954182A1 (en) 2016-01-14
CU20170001A7 (es) 2017-04-05
IL249660B (en) 2022-02-01
EP3166615B1 (en) 2023-08-09
CA2954182C (en) 2023-08-15
KR102734495B1 (ko) 2024-11-25
DOP2017000002A (es) 2017-03-15
BR112017000320A2 (pt) 2017-11-07
SMT202300380T1 (it) 2024-01-10
DK3166615T3 (da) 2023-11-13
ECSP16097355A (es) 2017-03-31
MX381042B (es) 2025-03-12
AU2015286199B2 (en) 2020-05-14
CL2017000008A1 (es) 2017-06-09
PH12017500010A1 (en) 2017-05-15
JP2020143065A (ja) 2020-09-10
LT3166615T (lt) 2024-01-25
CN113750112A (zh) 2021-12-07
MD4760B1 (ro) 2021-07-31
TWI766831B (zh) 2022-06-11
US20160008393A1 (en) 2016-01-14
SI3166615T1 (sl) 2023-12-29
ES2963814T3 (es) 2024-04-02
NZ727583A (en) 2024-08-30
PT3166615T (pt) 2023-11-13
MX2017000053A (es) 2017-05-01
IL249660A0 (en) 2017-02-28
BR112017000320B1 (pt) 2023-02-07
MD20170014A2 (ro) 2017-07-31
MY178087A (en) 2020-10-02
SG11201700073PA (en) 2017-02-27
FI3166615T3 (fi) 2023-11-06
EA036745B1 (ru) 2020-12-16
KR20170029577A (ko) 2017-03-15
HRP20231400T1 (hr) 2024-02-16
EP3166615A1 (en) 2017-05-17
PH12017500010B1 (en) 2022-07-29
PL3166615T3 (pl) 2024-02-19
TW201613617A (en) 2016-04-16
HK1231402A1 (zh) 2017-12-22
EP3166615A4 (en) 2018-01-17
KR20230070330A (ko) 2023-05-22
WO2016004525A1 (en) 2016-01-14
JP6922030B2 (ja) 2021-08-18
JP2017521433A (ja) 2017-08-03
EA201790160A1 (ru) 2017-06-30
US9603865B2 (en) 2017-03-28

Similar Documents

Publication Publication Date Title
RS64833B1 (sr) Helatni fosforotioatni polimeri nukleinske kiseline za upotrebu u kombinaciji sa inhibitorom hbv polimeraze za lečenje virusnih infekcija hepatitisa b i hepatitisa d
US12173289B2 (en) Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof
TWI620568B (zh) 用於治療ｂ型肝炎及ｄ型肝炎感染之方法
US20180179542A1 (en) OLIGONUCLEOTIDE TARGETING STRATEGY FOR cccDNA
TW202221122A (zh) Ｂ型肝炎患者之寡核苷酸治療
HK40065449A (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
OA21432A (en) Hepatitis b virus (HBV) dsRNA agent compositions and methods of use thereof.
OA20174A (en) Hepatitis B Virus (HBV) dsRNA Agent Compositions And Methods Of Use Thereof
EA048263B1 (ru) КОМПОЗИЦИИ АГЕНТОВ дцРНК ВИРУСА ГЕПАТИТА B (HBV) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
HK1210022B (zh) 治疗乙型肝炎及丁型肝炎感染的方法